טוען...
Tissue plasminogen activator-based nanothrombolysis for ischemic stroke
INTRODUCTION: Thrombolysis with intravenous tissue plasminogen activator (tPA) is the only FDA approved treatment for patients with acute ischemic stroke, but its use is limited by narrow therapeutic window, selective efficacy, and hemorrhagic complication. In the past two decades, extensive efforts...
שמור ב:
| הוצא לאור ב: | Expert Opin Drug Deliv |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5780255/ https://ncbi.nlm.nih.gov/pubmed/28944694 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/17425247.2018.1384464 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|